title: Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin.
abstract: OBJECTIVE
  The dysmetabolic iron overload syndrome (DIOS) is a common disorder but its origin remains unclear.
  
  
  METHODS
  A case-control study was conducted to compare intestinal absorption of iron in 16 men with DIOS (age 53 +/- 11 years, serum ferritin 750 +/- 372 microg/l, hepatic iron 78 +/- 25 micromol/g) and in 32 age-matched controls with normal body iron stores (16 overweight subjects and 16 lean subjects). Intestinal absorption was calculated as the area under the curve (AUC) of 58Fe administered orally and correlated with plasma hepcidin and with insulin resistance parameters including HOMA.
  
  
  RESULTS
  Intestinal iron absorption was lower in DIOS (AUC = 22.4 +/- 15.9 microg/l/h) compared to both overweight controls (AUC = 40.5 +/- 29.4 microg/l/h, p=0.04) and to lean controls (AUC = 102.5 +/- 113.5 microg/l/h, p < 0.01). There was an inverse correlation between intestinal iron absorption and plasma hepcidin (r = -0.61, p < 0.001), HOMA (r = -0.35, p = 0.01) and C reactive protein (r = -0.52, p < 0.001).
  
  
  CONCLUSIONS
  In overweight subjects with normal iron stores, iron absorption is decreased through hepcidin upregulation. In patients with DIOS, this decrease is more pronounced due to an additional effect of iron excess on circulating hepcidin levels.
authors.affiliation: Service de Médecine Interne, Hôtel Dieu, CHU de Clermont-Ferrand, 63058 Clermont-Ferrand Cedex 1, France. mruivard@chu-clermontferrand.fr
authors.forename: Marc
authors.initials: M
authors.lastname: Ruivard
authors.forename: Fabrice
authors.initials: F
authors.lastname: Lainé
authors.forename: Tomas
authors.initials: T
authors.lastname: Ganz
authors.forename: Gordana
authors.initials: G
authors.lastname: Olbina
authors.forename: Mark
authors.initials: M
authors.lastname: Westerman
authors.forename: Elizabeta
authors.initials: E
authors.lastname: Nemeth
authors.forename: Mathieu
authors.initials: M
authors.lastname: Rambeau
authors.forename: André
authors.initials: A
authors.lastname: Mazur
authors.forename: Laurent
authors.initials: L
authors.lastname: Gerbaud
authors.forename: Valérie
authors.initials: V
authors.lastname: Tournilhac
authors.forename: Armand
authors.initials: A
authors.lastname: Abergel
authors.forename: Pierre
authors.initials: P
authors.lastname: Philippe
authors.forename: Yves
authors.initials: Y
authors.lastname: Deugnier
authors.forename: Charles
authors.initials: C
authors.lastname: Coudray
mesh_terms: D000328:Adult; D000368:Aged; D023181:Antimicrobial Cationic Peptides / Q000097:blood*; D016022:Case-Control Studies; D064451:Hepcidins; D006801:Humans; D007333:Insulin Resistance; D007408:Intestinal Absorption; D007503:Iron Isotopes / Q000493:pharmacokinetics; D019190:Iron Overload / Q000097:blood* / Q000150:complications / Q000378:metabolism*; D019266:Iron, Dietary / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D050177:Overweight / Q000097:blood / Q000150:complications / Q000378:metabolism; D013577:Syndrome
chemical_list: D023181:Antimicrobial Cationic Peptides; C578702:HAMP protein, human; D064451:Hepcidins; D007503:Iron Isotopes; D019266:Iron, Dietary